gene editing firm’s stock faces pivotal year By Investing.com
Caribou Biosciences, Inc. (NASDAQ:CRBU), a biotechnology company specializing in CRISPR gene editing technology with a market capitalization of $183 million, stands at a critical juncture as it advances its clinical pipeline and innovative HLA-matching strategy. The stock has experienced significant pressure in 2024, with a year-to-date decline of 66%, though InvestingPro analysis suggests the company may be undervalued at current levels. The company’s focus on developing therapies for cancer and autoimmune disorders has garnered attention from analysts and investors alike, with its stock performance closely tied to the progress of its clinical trials and the potential validation of its scientific approach.
